Cyclosporine A and mycophenolate mofetile as prophylactics for GVHD in a murine model of H-2 haploidentical nonmyeloablative bone marrow transplantation.
- Author:
Xin LI
1
;
Yi ZHANG
;
Wang-Jun SUN
;
Chun-Mei HOU
;
Ming-Wei ZHANG
;
Ying WU
;
Ning MAO
;
Hui-Sheng AI
Author Information
1. Department of Hematology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100039, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Marrow Transplantation;
immunology;
Cyclosporine;
therapeutic use;
Graft vs Host Disease;
mortality;
prevention & control;
H-2 Antigens;
genetics;
Hematopoiesis;
Immunosuppressive Agents;
therapeutic use;
Male;
Mice;
Mice, Inbred C57BL;
Models, Animal;
Mycophenolic Acid;
analogs & derivatives;
therapeutic use;
Transplantation Chimera
- From:
Journal of Experimental Hematology
2003;11(4):420-423
- CountryChina
- Language:Chinese
-
Abstract:
In order to research the prophylactic effect of cyclosporine A (CSA) and mycophenolate mofetile (MMF) on GVHD in mice with H-2 haploidentical nonmyeloablative bone marrow transplantation, a murine model was established by using of C57BL/6J mouse as donor and (C57BL/6J x BALB/C) F(1) mouse as the recipient. The recipient mice were given CSA + MTX or CSA + MMF for prophylaxis of acute GVHD (aGVHD). The survival rate, hematopoietic recovery, and morbidity and mortality of aGVHD were observed for 50 days after transplantation. The results showed that typical aGVHD developed in the transplanted mice without prophylactic treatment during 22 to 25 days after transplantation. The morbidity of aGVHD was 75% (15/20), 40% (8/20) and 30% (6/20) and mortality was 100% (15/15), 62.5% (5/8) and 50% (3/6) respectively in unprophylactic group (control), CSA + MTX and CSA + MMF groups. In conclusion, CSA and MTX reduce the morbidity and mortality of aGVHD in mice with haploidentical nonmyeloablative bone marrow transplantation, and the effect of CSA + MMF is better than that of CSA + MTX.
